Ascendis Pharma's TransCon CNP Wins Positive CHMP Opinion for Childhood Achondroplasia

CHMP recommends EU authorization of Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged two or older with open epiphyses. A final European Commission decision is expected in the fourth quarter of 2026. If authorized, the first EU launch is planned in Germany in the first quarter of 2027 under the YUVIWEL brand. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via (Ref. ID: 202610160829PRIMZONEFULLFEED9847367) on October 16, 2026, and is solely responsible for the information contained therein. (C)